211 related articles for article (PubMed ID: 24057195)
21. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases.
Perez-Rodriguez J; Lai S; Ehst BD; Fine DM; Bluemke DA
Radiology; 2009 Feb; 250(2):371-7. PubMed ID: 19188312
[TBL] [Abstract][Full Text] [Related]
22. [Nephrogenic systemic fibrosis: a rare disease with grave consequences].
Kielstein JT; Schiffer M
Internist (Berl); 2010 Jan; 51(1):39-44. PubMed ID: 20033388
[TBL] [Abstract][Full Text] [Related]
23. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines.
Thomsen HS; Morcos SK; Almén T; Bellin MF; Bertolotto M; Bongartz G; Clement O; Leander P; Heinz-Peer G; Reimer P; Stacul F; van der Molen A; Webb JA;
Eur Radiol; 2013 Feb; 23(2):307-18. PubMed ID: 22865271
[TBL] [Abstract][Full Text] [Related]
24. Correction to the relative risk calculation for gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis.
Jain R; Levine M
Radiology; 2010 Apr; 255(1):307-8; author reply 308. PubMed ID: 20308469
[No Abstract] [Full Text] [Related]
25. Nephrogenic systemic fibrosis and management of high-risk patients.
Altun E; Semelka RC; Cakit C
Acad Radiol; 2009 Jul; 16(7):897-905. PubMed ID: 19375360
[TBL] [Abstract][Full Text] [Related]
26. Nephrogenic systemic fibrosis and gadolinium-containing radiological contrast agents: an update.
Jalandhara N; Arora R; Batuman V
Clin Pharmacol Ther; 2011 Jun; 89(6):920-3. PubMed ID: 21471962
[No Abstract] [Full Text] [Related]
27. Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium - 1997-2006-2016. Part 1.
Thomsen HS
Acta Radiol; 2016 May; 57(5):515-20. PubMed ID: 26802069
[No Abstract] [Full Text] [Related]
28. Gadolinium-based contrast agents in children.
Rozenfeld MN; Podberesky DJ
Pediatr Radiol; 2018 Aug; 48(9):1188-1196. PubMed ID: 30078039
[TBL] [Abstract][Full Text] [Related]
29. Nephrogenic systemic fibrosis.
Weinreb JC; Kuo PH
Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
[TBL] [Abstract][Full Text] [Related]
30. Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines.
Nacif MS; Arai AE; Lima JA; Bluemke DA
J Cardiovasc Magn Reson; 2012 Feb; 14(1):18. PubMed ID: 22376193
[TBL] [Abstract][Full Text] [Related]
31. Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis.
Bhave G; Lewis JB; Chang SS
J Urol; 2008 Sep; 180(3):830-5; discussion 835. PubMed ID: 18635232
[TBL] [Abstract][Full Text] [Related]
32. Nephrogenic systemic fibrosis: the need for accurate case reporting.
Spinazzi A; Kirchin MA; Pirovano G
J Magn Reson Imaging; 2009 May; 29(5):1240; author reply 1241. PubMed ID: 19388104
[No Abstract] [Full Text] [Related]
33. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
Weinreb JC; Abu-Alfa AK
J Magn Reson Imaging; 2009 Dec; 30(6):1236-9. PubMed ID: 19938035
[TBL] [Abstract][Full Text] [Related]
34. [Nephrogenic systemic fibrosis: a severe complication of use to gadolinium in patients with kidney failure].
Mundim JS; Lorena Sde C; Abensur H; Elias RM; Moysés RM; Castro MC; Romão Júnior JE
Rev Assoc Med Bras (1992); 2009; 55(2):220-5. PubMed ID: 19488662
[TBL] [Abstract][Full Text] [Related]
35. Gadolinium and nephrogenic systemic fibrosis.
Runge VM
AJR Am J Roentgenol; 2009 Apr; 192(4):W195-6; discussion W197. PubMed ID: 19304681
[No Abstract] [Full Text] [Related]
36. Nephrogenic systemic fibrosis: concepts and perspectives.
Igreja AC; Mesquita Kde C; Cowper SE; Costa IM
An Bras Dermatol; 2012; 87(4):597-607. PubMed ID: 22892775
[TBL] [Abstract][Full Text] [Related]
37. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogénique Systémique study.
Amet S; Launay-Vacher V; Clément O; Frances C; Tricotel A; Stengel B; Gauvrit JY; Grenier N; Reinhardt G; Janus N; Choukroun G; Laville M; Deray G
Invest Radiol; 2014 Feb; 49(2):109-15. PubMed ID: 24169070
[TBL] [Abstract][Full Text] [Related]
38. Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors.
Bahrami S; Raman SS; Sauk S; Salehmoghaddam S; Villablanca JP; Finn JP; Lu DS
J Comput Assist Tomogr; 2009; 33(6):819-23. PubMed ID: 19940643
[TBL] [Abstract][Full Text] [Related]
39. Nephrogenic systemic fibrosis and gadolinium-based contrast agents.
Abu-Alfa AK
Adv Chronic Kidney Dis; 2011 May; 18(3):188-98. PubMed ID: 21531325
[TBL] [Abstract][Full Text] [Related]
40. Pathomechanisms of nephrogenic systemic fibrosis: new insights.
Gupta A; Shamseddin MK; Khaira A
Clin Exp Dermatol; 2011 Oct; 36(7):763-8. PubMed ID: 21790732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
